You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Details for Patent: 8,337,890

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,337,890 protect, and when does it expire?

Patent 8,337,890 protects DYANAVEL XR 10, DYANAVEL XR 15, DYANAVEL XR 20, DYANAVEL XR 5, and NEXICLON XR, and is included in two NDAs.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 8,337,890

Title:	Modified release formulations containing drug-ion exchange resin complexes
Abstract:	A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
Inventor(s):	Mehta; Ketan (Cranbury, NJ), Tu; Yu-Hsing (West Windsor, NJ)
Assignee:	Tris Pharma Inc (Monmouth Junction, NJ)
Application Number:	12/722,857
Patent Claim Types: see list of patent claims	Composition; Process; Dosage form;

Drugs Protected by US Patent 8,337,890

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tris Pharma Inc	DYANAVEL XR 10	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-002	Nov 4, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Tris Pharma Inc	DYANAVEL XR 15	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-003	Nov 4, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Tris Pharma Inc	DYANAVEL XR 20	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-004	Nov 4, 2021		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Tris Pharma Inc	DYANAVEL XR 5	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-001	Nov 4, 2021		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Athena	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-001	Dec 3, 2009		RX	No	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Athena	NEXICLON XR	clonidine	TABLET, EXTENDED RELEASE;ORAL	022500-002	Dec 3, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,337,890

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E536867	⤷ Sign Up
Australia	2007227569	⤷ Sign Up
Brazil	PI0709606	⤷ Sign Up
Canada	2645855	⤷ Sign Up
China	101400343	⤷ Sign Up
China	102488652	⤷ Sign Up
Denmark	2018160	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.